Moderators: Ana Oaknin, MD & Wendel Naumann, MD 

Presentations:

• Interim Post-Progression Data and Updated Survival in Patients with Newly Diagnosed Advanced Ovarian Cancer in ATHENA-MONO (Rebecca S. Kristeleit, MD PhD)
• Patient-Reported Outcome Results from Phase III MIRASOL Trial of mirvetuximab soravtansine vs. Investigator’s Choice of Chemotherapy in FRα Positive Platinum-resistant Ovarian Cancer (Gottfried E. Konecny, MD)
• Efficacy and safety of alpelisib (ALP) + olaparib (OLA) vs chemotherapy (CT) in patients (pts) with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC) without BRCA mutation: primary analysis of the EPIK-O trial (Panagiotis A. Konstantinopoulos, MD, PhD)
• A Phase II/III Study of cediranib and olaparib Combination Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Platinum-Resistant Ovarian Cancer (NRG-GY005) (Jung-Min Lee, MD)
• Distillation: Scientific Plenary II: Challenges in Drug Development (Michael Bookman, MD)
• Neoadjuvant Camrelizumab plus Chemotherapy for Locally Advanced Cervical Cancer (NACI study): A Prospective, Single-arm, Phase II trial (Yingjie Hu, MD)
• Neoadjuvant tislelizumab plus chemotherapy in patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial (Jindong Sheng, MD)
• (LBA) Survival of patients with early stage cervical cancer after sentinel lymph node biopsy without systematic pelvic lymphadenectomy: Primary endpoint outcome of the SENTIX prospective single-arm international trial (CEEGOG CX-01; ENGOT-CX2) (David Cibula, MD)
• Distillation on NACI study and outcome of the SENTIX prospective single-arm international trial (CEEGOG CX-01; ENGOT-CX2) (Domenica Lorusso, MD, PhD)